Novogene(SH:688315) Shang Hai Zheng Quan Bao·2025-09-01 20:00Group 1 - The company announced the resignation of non-independent director Wang Qifeng due to adjustments in the corporate governance structure, but he will continue to work at the company [1][3] - Wang Qifeng was elected as the employee representative director during the company's second employee representative assembly held on September 1, 2025, with a term aligned with the fourth board of directors [1][4] - The resignation of Wang Qifeng will not affect the normal operation of the board or the company's daily operations, as it does not reduce the board members below the legal minimum [3][5] Group 2 - The company held its third meeting of the fourth board of directors on September 1, 2025, where members of the strategic committee and the remuneration and assessment committee were elected [2][6] - The remuneration and assessment committee consists of a majority of independent directors, with an independent director serving as the chairperson [6][7] - The term for the newly elected committee members will last until the end of the fourth board's term [6][7] Group 3 - The company convened its first extraordinary general meeting of shareholders on September 1, 2025, where all proposed resolutions were approved without any being rejected [8][9] - The meeting was conducted in compliance with relevant laws and regulations, with all board members and the board secretary present [10][11] - The resolutions included the cancellation of the supervisory board and amendments to the company's articles of association, which were passed with the required majority [10][11]